Bio-Rad Laboratories reported $656.4 million in revenue for Q3 2026.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0000012208-26-000058
- Revenue: $656.4 million for the three months ended Sep 30, 2026
- Net income: $458.6 million for the three months ended Sep 30, 2026
- Diluted EPS: $17.02 for the three months ended Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
The reading, claim by claim
- In the income statement (in millions), net sales were $656.4 million for the three months, against $653.0 million a year earlier.
- Gross profit was $328.6 million, and the filing records an impairment of purchased intangibles of $49.8 million.
- Loss from operations was $49.7 million, compared with income of $65.3 million a year earlier.
- Net income of $458.6 million compares with a net loss of $341.9 million in the 2025 quarter.
- The statements show gains of $588.2 million from change in fair market value of equity securities and loan receivable, against a $495.3 million loss a year earlier.
- Diluted earnings per share were $17.02, versus a loss of $12.70.
- Net cash provided by operating activities was $303.2 million, compared with $367.3 million in the same period of 2025.
- Purchases of property, plant and equipment were $93.2 million.
- At September 30, 2026, the balance sheet shows cash and cash equivalents of $465.3 million and short-term investments of $1,199.0 million.
- Current maturities of long-term debt and notes payable were $400.9 million, against $1.3 million at December 31, 2025.
- Total assets were $10,783.1 million.
- The filing's forward-looking statements section lists risks that include its position in Sartorius AG.
12 of 13 claims matched the filing text.
Not found in the filing text
- For the nine months, net sales were $1,899.5 million and net income was $302.9 million.
From the filing's financial data, not stated in its text
From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026
- The financial statements report revenue of $656.4 million and net income of $458.6 million for the quarter, with revenue up 0.5% from a year earlier.
From the filing
Item 6.
Item 6.
Exhibits
56
Signatures
57
2
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Other than statements of historical fact, statements made in this report include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our future financial performance, operating results, plans and objectives. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," "seek," "future," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, the risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, supply chain issues, risks associated with our position in Sartorius AG12, risks to our information technology systems, intellectual property risks, our ability to attract and retain key personnel, international legal and regulatory risks, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, natural disasters and other catastrophic events beyond our control, and other risks and uncertainties identified under "Part II, Item 1A, Risk Factors" of this Quarterly Report on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
3
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
Item 1. Financial Statements
BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(In millions, except share data)
September 30, 2026 December 31, 2025
ASSETS
(Unaudited)
Current assets:
Property, plant and equipment, net 505.7 539.9
Operating lease right-of-use assets 147.1 170.0
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets (continued)
(In millions, except share data)
September 30, 2026 December 31, 2025
LIABILITIES AND STOCKHOLDERS' EQUITY
(Unaudited)
Current liabilities:
Accounts payable $ 133.5 $ 129.0
Accrued payroll and employee benefits 210.3 172.3
Current maturities of long-term debt and notes payable 400.9 1.310
Income and other taxes payable 37.8 36.6
Long-term debt, net of current maturities 803.1 1,201.7
Stockholders' equity:
Preferred stock, $ 0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none
— —
Class A common stock, $ 0.0001 par value; 80,000,000 shares authorized; shares issued - 25,205,055 and 25,199,760 as of September 30, 2026 and December 31, 2025, respectively; shares outstanding - 21,830,094 and 21,924,284 as of September 30, 2026 and December 31, 2025, respectively
— —
Class B common stock, $ 0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,060,815 as of September 30, 2026 and 5,066,110 as of December 31, 2025, respectively
— —
Accumulated other comprehensive income (loss) ( 315.3 ) ( 189.1 )
Total stockholders' equity 7,603.0 7,453.6
Total liabilities and stockholders' equity $ 10,783.1 $ 10,576.5
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Income (Loss)
(In millions, except number of shares, which are reflected in thousands, and per share data)
(Unaudited)
Three Months Ended Nine Months Ended
Basic earnings (loss) per share:
Net income (loss) per basic share
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Comprehensive Income (Loss)
(In millions, unaudited)
Three Months Ended Nine Months Ended
Net income (loss)
Net unrealized holding gains (losses) on cash flow hedge
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(In millions, unaudited)
Nine Months Ended
September 30,
Cash paid to suppliers and employees ( 1,607.8 ) ( 1,511.4 )
Dividend proceeds and miscellaneous receipts, net
65.4 62.7
Proceeds from (payments for) forward foreign exchange contracts, net 15.8 ( 42.9 )
Net cash provided by operating activities 303.2 367.37
Cash flows from investing activities:
Payments for purchases of property, plant and equipment ( 93.2 ) ( 111.8 )8
Proceeds from dispositions of property, plant and equipment — 0.1
(Payments for) proceeds from acquisitions, net of cash received 1.1 ( 218.5 )
Payments for purchases of marketable securities and in
Similar companies
Companies of similar size in SIC 3826 and related industry codes: the same peer list as the financial tables.